Is Moderna Stock Underperforming the S&P 500?

With a market capitalization hovering around $10 billion, Massachusetts-based Moderna, Inc. (MRNA) is a clinical-stage pharmaceutical company focused on developing messenger RNA (mRNA)–based therapies. Leveraging mRNA technology, Moderna is revolutionizing the way medicines are developed, enabling the faster creation of treatments and vaccines for a range of diseases. Over more than a decade, the company has advanced therapies at a notable speed, including one of the first widely used COVID-19 vaccines.

Companies valued at $10 billion or more are typically classified as "large-cap" stocks, and Moderna sits near this threshold. The company’s mRNA platform supports research and development in infectious diseases, immuno-oncology, rare diseases, and autoimmune conditions. Backed by a global team guided by its core values, Moderna continues to push the boundaries of how science and technology intersect with human health.